Gyre Therapeutics Inc (STU:L9S)
€ 12.3 0.3 (2.5%) Market Cap: 1.17 Bil Enterprise Value: 1.15 Bil PE Ratio: 0 PB Ratio: 19.89 GF Score: 30/100

Catalyst Biosciences, Inc. - Special Call Transcript

Aug 15, 2019 / 04:00PM GMT
Unidentified Participant

Good afternoon, everyone, and thank you for attending our KOL event today hosted by Catalyst Biosciences on next generation Factor VIIa Marzeptacog alfa activated or MarzAA, in patients with bleeding disorders. Today, we'll be hearing from 2 hemophilia experts in the field of hemophilia, Dr. Robert Klamroth and Dr. Steven Pipe. We will also be hearing from the senior members of the management team, Dr. Howard Levy, our Chief Medical Officer; Jeff Landau, VP of Business Development, Grant Blouse, VP of translational research; Fletcher Payne, whose last name takes on particular significance today, our Chief Financial Officer; and Nassim Usman. With that, I will open the floor to Dr. Nassim Usman.

Nassim Usman
Catalyst Biosciences, Inc. - President, CEO & Director

Great. Thank you everyone for attending today, and welcome to our MarzAA KOL luncheon. I'm very pleased that we have a great turnout, and I hope you're going to learn a lot from our 2 speakers today who have been working in the hemophilia field for a long time and other rare

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot